BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 7199300)

  • 41. Dilazep-induced reduction of ischemic necrosis in rats with coronary artery occlusion.
    Chiariello M; Brevetti G; Genovese A; Cataffo A; Ambrosio G; Condorelli M
    Int J Cardiol; 1983; 2(3-4):339-48. PubMed ID: 6840902
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Depletion of membrane phospholipid and mitochondrial dysfunction associated with coronary reperfusion.
    Hattori M; Ogawa K; Satake T; Sugiyama S; Ozawa T
    Basic Res Cardiol; 1985; 80(3):241-50. PubMed ID: 4026784
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cardiovascular effects of a single high dose of dilazep by oral route.
    Ibba GV; Terrosu P; Franceschino V; Contini GM
    Int J Cardiol; 1986 Jun; 11(3):337-48. PubMed ID: 3721632
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Proceedings: Influence of hypertonic mannitol on regional myocardial blood flow during and in the absence of acute myocardial ischaemia in the conscious intact dog.
    Hutton I; Templeton GH; Fixler DE; Willerson JT
    Br Heart J; 1974 Apr; 36(4):402. PubMed ID: 4842634
    [No Abstract]   [Full Text] [Related]  

  • 45. Potentiation by dilazep on the negative inotropic effect of adenosine on guinea-pig atria.
    Fujita S; Ishida Y; Izumi K; Moritoki H; Ohara M; Takei M
    Br J Pharmacol; 1980 Feb; 68(2):343-9. PubMed ID: 7357212
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Effect of benzodiazepine tranquilizers on the ischemic focus and redistribution of blood flow in the ischemic myocardium].
    Chichkanov GG; Bogolepov AK; Matsievskiĭ DD
    Biull Eksp Biol Med; 1984 Apr; 97(4):429-31. PubMed ID: 6722303
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of K-7259, a novel derivative of dilazep, on cardiovascular actions of adenosine: comparison with dilazep.
    Hara A; Akahira M; Abiko Y
    Arch Int Pharmacodyn Ther; 1995; 330(1):66-75. PubMed ID: 8849311
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Contemporaneous administration of digitalis and dilazep to subjects with heart failure of ischemic etiology.
    Pasotti C; Gandolfi P; Ottolenghi L
    Int J Clin Pharmacol Ther Toxicol; 1983 Jul; 21(7):370-3. PubMed ID: 6885209
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of nitroglycerin with and without systemic hypotension on canine regional myocardial tritiated water deposition.
    Paradise NF; Tripp MR; Burchell HB; Gerasch DA; Swayze CR; Fox IJ
    Cardiovasc Res; 1976 Mar; 10(2):182-91. PubMed ID: 820429
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of dilazep (Comelian) on the central purinergic system: inhibitory effects on clonidine-induced aggressive behavior.
    Ushijima I; Mizuki Y; Hara T; Kaneyuki H; Mashimoto S; Kajimura N; Yamada M
    Eur J Pharmacol; 1989 Feb; 161(2-3):245-8. PubMed ID: 2721556
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phasic blood flow velocity pattern in epimyocardial microvessels in the beating canine left ventricle.
    Ashikawa K; Kanatsuka H; Suzuki T; Takishima T
    Circ Res; 1986 Dec; 59(6):704-11. PubMed ID: 3815760
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intravenous dilazep reduces blood pressure and peripheral vascular resistance in humans.
    Poggesi L; Masotti G; Serneri GG; Carnovali M
    J Clin Pharmacol; 1988 Jan; 28(1):43-7. PubMed ID: 3280614
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of dilazep on hemoglobin-oxygen affinity in patients with ischemic heart disease.
    Koshu M; Sugimoto T; Terada Y; Uraoka T
    Jpn Heart J; 1985 Jul; 26(4):521-30. PubMed ID: 3903248
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of dilazep on fibrinolytic system in animals. I. Enhancement of fibrinolytic activity by administered dilazep in ex vivo experiment.
    Nakajima K; Yamamoto S; Tsukamoto M; Nagakura M
    J Pharmacobiodyn; 1982 May; 5(5):356-62. PubMed ID: 6181245
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Results of the clinical testing of a new coronary drug, Cormelian].
    Pollter J
    Fortschr Med; 1972 Apr; 90(10):399-404. PubMed ID: 4616888
    [No Abstract]   [Full Text] [Related]  

  • 56. Coronary blood flow during variation in coronary perfusion pressure.
    Coetzee A; Foëx P; Holland D; Ryder A; Jones L
    S Afr Med J; 1985 Jul; 68(1):15-8. PubMed ID: 4012486
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Behavior of heart rate and systolic arterial pressure during isometric exercise after administration of salbutamol, dilazep, indomethacin and a placebo].
    Arosio A; Sergi M; Grisetti GC; Mandelli V; Bosisio E
    Minerva Cardioangiol; 1982 Jun; 30(6):309-12. PubMed ID: 7133419
    [No Abstract]   [Full Text] [Related]  

  • 58. Coronary blood flow in oligemic hypotension.
    Yarbrough DR; Yoakum S; Barnes M; Weidner MG
    Surg Forum; 1969; 20():26-8. PubMed ID: 5383064
    [No Abstract]   [Full Text] [Related]  

  • 59. [Cormelian (Dilazep) a new coronary active substance].
    Reuter H
    Z Allgemeinmed; 1974 Oct; 50(28):1255-6. PubMed ID: 4614598
    [No Abstract]   [Full Text] [Related]  

  • 60. [Induction of coronary vascularization by dilazep in experimental animals].
    Schmitt G; Winter R; St Müller U; Hauss WH
    Arzneimittelforschung; 1972 Apr; 22(4):663-6. PubMed ID: 5068244
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.